NCT02594761View on ClinicalTrials.gov

Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

Hercules

Powder Concentrate for Intravenous Infusion, 150 mg/vial

BIOLOGICAL

Herceptin EU

Powder for Concentrate for Solution for Infusion, 150 mg/vial

BIOLOGICAL

Herceptin US

Intravenous Infusion, 440 mg/vial

Sponsors
All Listed Sponsors
collaborator

Mylan GmbH

INDUSTRY

lead

Mylan Pharmaceuticals Inc

INDUSTRY